PCSK9 and atherosclerosis: In their meta-analysis of 39 randomized controlled studies, Guedeney et al. [98] assessed the efficacy of Alirocumab and Evolocumab in patients with abnormal lipid levels or ASCVD, involving 66,478 patients, with 35,896 receiving PCSK9 inhibitors.